针对泛性性牛皮的生物疗法的临床进展:一篇综述
Chang-Yu Hsieh1, Tsen-Fang Tsai1
1Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan.
Expert opinion on biological therapy
|January 22, 2024
概括
美国食品和药物管理局批准了斯佩索利马布用于一般性性牛皮 (GPP) 爆发. 这种生物向IL-36,提供了新的希望,特别是对于IL36RN突变的患者.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 泛性性牛皮 (GPP) 是一种严重的炎症状况.
- IL-36信号传递是GPP病变发生的一个关键途径.
- IL36RN突变在GPP中很常见,并影响疾病特征.
研究的目的:
- 审查关于生物治疗GPP的文献.
- 评估IL36RN突变在GPP治疗反应中的作用.
- 讨论斯佩索利马布批准对GPP管理的影响.
主要方法:
- 在PubMed,Embase和ClinicalTrials.gov.gov的综合文献搜索.
- 专注于涉及GPP生物学的研究,包括儿科和孕妇人群.
- 分析IL36RN突变对生物有效性的影响.
主要成果:
- 生物向IL-36的斯佩索利马布被FDA批准用于2022年GPP爆发.
- IL36RN突变与GPP相关,可能影响治疗结果.
- 初步数据表明,在患有致病性IL36RN突变的患者中,生物药物可能具有更好的疗效.
结论:
- 斯佩索利马布的批准预示着GPP的新治疗时代.
- 需要进一步的研究,包括随机试验,以确认在特定人群 (儿科,孕妇) 中的有效性和安全性.
- 药物遗传学,特别是IL36RN突变状态,可能指导未来的GPP治疗决策.
相关概念视频
iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
139
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
139


